Certified by Founder Lodge
Frazier Life Sciences
United States - ND
INVESTOR
1 Disclosed Funding Rounds $85,000,000
8 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences funds comprise o
| Company | Date | Round | Raised |
|---|---|---|---|
 Lassen Therapeutics |
December, 21 ,2023 | Series B | $85,000,000 |
 Sudo Biosciences |
December, 21 ,2023 | Series B | $116,000,000 |
 Radionetics Oncology |
January, 04 ,2024 | Series A | $52,500,000 |
 Bluejay Therapeutics |
May, 10 ,2024 | Series C | $182,000,000 |
 Attovia Therapeutics |
May, 14 ,2024 | Series B | $105,000,000 |
 Scorpion Therapeutics |
July, 17 ,2024 | Series C | $150,000,000 |
 Alpha-9 Oncology |
October, 24 ,2024 | Series C | $175,000,000 |
 Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
TG0 | $5,619,170 | (Dec 20, 2024)
Double(US) | $3,900,000 | (Dec 20, 2024)
Mindgard | $8,000,000 | (Dec 20, 2024)
Hauler Hero | $10,000,000 | (Dec 20, 2024)
LeapFinancial | $3,500,000 | (Dec 20, 2024)
